Table 3 Changes in IMT from baseline at 104 weeks in patients treated with or without sitagliptin in subgroup analysis based on the occurrence of hypoglycemia.

From: Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus

Parameters Hypoglycemia Sitagliptin group Conventional group P value
Change in mean IMT-CCA No −0.057 ± 0.140 (n = 72)§ 0.012 ± 0.138 (n = 73) 0.003
Yes 0.012 ± 0.201 (n = 49) 0.042 ± 0.135 (n = 49)* 0.38
Change in right max IMT-CCA No −0.039 ± 0.243 (n = 72) 0.041 ± 0.412 (n = 73) 0.16
Yes 0.062 ± 0.470 (n = 48) −0.007 ± 0.295 (n = 49) 0.39
Change in left max IMT-CCA No −0.105 ± 0.298 (n = 72)# −0.003 ± 0.304 (n = 73) 0.042
Yes −0.005 ± 0.393 (n = 49) 0.060 ± 0.266 (n = 49) 0.34
  1. Data are mean ± SD. Differences in parameters from baseline to 104 weeks within group were analyzed by one-sample t-test. Differences in parameters from baseline to 104 weeks between groups were analyzed by the Student’s t-test. *P < 0.05, #P < 0.01, §P < 0.001.